Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,9010710,area under the plasma concentration-time curve,"For the area under the plasma concentration-time curve calculated from time 0 to a concentration greater than zero, AUC(O-t), the study showed a mean value of moexipril 437 ng.",Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010710/),ng,437,60447,DB00691,Moexipril
,9010710,Cmax,The Cmax of moexipril and the metabolite (data of the metabolite in parenthesis) were 245.4 (70.8) ng.ml-1 after administration of moexipril alone and 241.0 (69.2) ng.ml-1 after coadministration of hydrochlorothiazide.,Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010710/),[ng] / [ml],245.4,60448,DB00691,Moexipril
,9010710,Cmax,The Cmax of moexipril and the metabolite (data of the metabolite in parenthesis) were 245.4 (70.8) ng.ml-1 after administration of moexipril alone and 241.0 (69.2) ng.ml-1 after coadministration of hydrochlorothiazide.,Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010710/),[ng] / [ml],241.0,60449,DB00691,Moexipril
,9010710,total renal excretion (TUE),The mean total renal excretion (TUE) of hydrochlorothiazide was 15.2 mg when administered alone and 15.1 mg when given together with moexipril.,Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010710/),mg,15.2,60450,DB00691,Moexipril
,9010710,total renal excretion (TUE),The mean total renal excretion (TUE) of hydrochlorothiazide was 15.2 mg when administered alone and 15.1 mg when given together with moexipril.,Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010710/),mg,15.1,60451,DB00691,Moexipril
,9010710,TUE-,The corresponding mean TUE-values for moexiprilat were 334 (1200) and 453 (1460) micrograms.,Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010710/),μg,334,60452,DB00691,Moexipril
,9010710,TUE-,The corresponding mean TUE-values for moexiprilat were 334 (1200) and 453 (1460) micrograms.,Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010710/),μg,453,60453,DB00691,Moexipril
,8276058,oral plasma clearance,"Mean oral plasma clearance of (R)-warfarin was 175 ml.h-1 in the absence and 181 ml.h-1 in the presence of moexipril, and the corresponding values for (S)-warfarin were 248 ml.h-1 and 249 ml.h-1.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),[ml] / [h],175,100317,DB00691,Moexipril
,8276058,oral plasma clearance,"Mean oral plasma clearance of (R)-warfarin was 175 ml.h-1 in the absence and 181 ml.h-1 in the presence of moexipril, and the corresponding values for (S)-warfarin were 248 ml.h-1 and 249 ml.h-1.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),[ml] / [h],181,100318,DB00691,Moexipril
,8276058,oral plasma clearance,"Mean oral plasma clearance of (R)-warfarin was 175 ml.h-1 in the absence and 181 ml.h-1 in the presence of moexipril, and the corresponding values for (S)-warfarin were 248 ml.h-1 and 249 ml.h-1.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),[ml] / [h],248,100319,DB00691,Moexipril
,8276058,oral plasma clearance,"Mean oral plasma clearance of (R)-warfarin was 175 ml.h-1 in the absence and 181 ml.h-1 in the presence of moexipril, and the corresponding values for (S)-warfarin were 248 ml.h-1 and 249 ml.h-1.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),[ml] / [h],249,100320,DB00691,Moexipril
,8276058,maximum prothrombin time,"Moexipril did not alter the maximum prothrombin time (20.3 versus 20.1 s, respectively in the absence and presence of moexipril), time to maximum response (48.0 versus 50 h) and area under the prothrombin time versus time curve.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),s,20.3,100321,DB00691,Moexipril
,8276058,maximum prothrombin time,"Moexipril did not alter the maximum prothrombin time (20.3 versus 20.1 s, respectively in the absence and presence of moexipril), time to maximum response (48.0 versus 50 h) and area under the prothrombin time versus time curve.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),s,20.1,100322,DB00691,Moexipril
,8276058,time to maximum response,"Moexipril did not alter the maximum prothrombin time (20.3 versus 20.1 s, respectively in the absence and presence of moexipril), time to maximum response (48.0 versus 50 h) and area under the prothrombin time versus time curve.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),h,48.0,100323,DB00691,Moexipril
,8276058,time to maximum response,"Moexipril did not alter the maximum prothrombin time (20.3 versus 20.1 s, respectively in the absence and presence of moexipril), time to maximum response (48.0 versus 50 h) and area under the prothrombin time versus time curve.",Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8276058/),h,50,100324,DB00691,Moexipril
,11837383,tmax,Moexiprilat tmax was 1.5-2 h with only minor differences between single and multiple dosing.,Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11837383/),h,1.5-2,110484,DB00691,Moexipril
,11837383,t 1/2,Moexiprilat showed a biphasic elimination phase with an average t 1/2 of 29-30 h.,Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11837383/),h,29-30,110485,DB00691,Moexipril
,11837383,trough concentrations,"The trough concentrations at 24 h did not fall below the limit of 1-2 ng/ml, i.e. a 50% ACE inhibition.",Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11837383/),[ng] / [ml],1-2,110486,DB00691,Moexipril
